about
Clinical and experimental applications of sodium phenylbutyrateAxitinib for the management of metastatic renal cell carcinomaThe safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitisPharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple MechanismsEfficacy and Safety Profile of Diclofenac/Cyclodextrin and Progesterone/Cyclodextrin Formulations: A Review of the Literature DataMolecular Insight in the Multifunctional Effects of OridoninImeglimin: A Potential New Multi-Target Drug for Type 2 DiabetesIdentifying and managing patients at high risk for fractures: conclusions from the second Spanish multidisciplinary forum-parathyroid hormone use in osteoporotic patients at high risk for fracturesImpact of respiratory syncytial virus: the nurse's perspectiveAn Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic DrugsLithium in Bipolar Disorder: Optimizing Therapy Using Prolonged-Release FormulationsCurrent and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its SymptomsSafety of Epidural Corticosteroid InjectionsmTOR: a potential therapeutic target in osteoarthritis?HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGenEfficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with Behçet's disease: a randomised, double-blind, placebo-controlled studyImmune modulation therapy-peripheral vascular disease--Vasogen (VasoCare)Does Ginkgo biloba special extract EGb 761 provide additional effects on coagulation and bleeding when added to acetylsalicylic acid 500 mg daily?Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--DendreonExisulind: Aptosyn, FGN 1, Prevatac, sulindac sulfoneMismatched double-stranded RNA: polyI:polyC12UPlerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791Icatibant: HOE 140, JE 049, JE049Impact of a Proprietary Standardized Olive Fruit Extract (SOFE) on Cardio-Ankle Vascular Index, Visual Analog Scale and C-Reactive Protein Assessments in Subjects with Arterial Stiffness RiskA Single Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Orally Administered Des-Aspartate Angiotensin I in Healthy SubjectsLerdelimumabSafety, Tolerability, and Pharmacokinetics of Etamicastat, a Novel Dopamine-β-Hydroxylase Inhibitor, in a Rising Multiple-Dose Study in Young Healthy SubjectsAssessing the Potential Cost-Effectiveness of Microneedle Patches in Childhood Measles Vaccination Programs: The Case for Further Research and Development.Antithyroid Drug-Induced Agranulocytosis: State of the Art on Diagnosis and ManagementRecent progress in anti-influenza chemotherapy.Use of adjectives in abstracts when reporting results of randomized, controlled trials from industry and academia.An in vitro analysis of disintegration times of different formulations of olanzapine orodispersible tablet: a preliminary report.Hsa-miR-520d converts fibroblasts into CD105+ populations.A comparison of two different formulations of diclofenac sodium 0.1% in the treatment of inflammation following cataract-intraocular lens surgery.Comparison of the analgesic effects of a fixed-dose combination of orphenadrine and diclofenac (Neodolpasse) with its single active ingredients diclofenac and orphenadrine: a placebo-controlled study using laser-induced somatosensory-evoked potentiaInvestigating pharmacology in vivo using magnetic resonance and optical imaging.Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes.Gliquidone contributes to improvement of type 2 diabetes mellitus management: a review of pharmacokinetic and clinical trial data.Identification of a Syndrome Class of Neuropsychiatric Adverse Reactions to Mefloquine from Latent Class Modeling of FDA Adverse Event Reporting System Data.
P1433
Q24613511-0CDAA976-00B7-4857-8BA5-59F6A145429FQ24613720-FDF8A89B-79FD-472D-A061-EB2600EA8424Q24631812-B8BD80E0-8EA5-42CE-A497-4C6915789673Q26751444-5C436C7A-E5A2-4ACE-84FD-25FB9EBB3498Q26768705-3710EEA6-EA28-4C87-82A1-A388726DCC17Q26796359-AE02AE45-C6BA-4348-9A6F-9108F9F089DAQ26800961-B9100564-5426-4881-911E-D418553D2204Q26858953-5204BC50-B833-47CA-952E-E52FA93A018EQ27023799-4291FAC7-3165-44CE-BD4F-3F56A419B051Q28069989-AC257810-03F1-4689-98B7-0B779D23A5EFQ28076935-57D637A4-1741-4747-BDDF-AFAD74E2D81CQ28077411-A0F4E788-1102-4ECD-9861-8E7D4EE147AAQ28077575-857C5A65-357D-47D7-899F-033E270A3024Q28087019-164341B7-D3F2-448A-8166-3237C35FCA55Q28185729-89CA3601-BF28-4759-BE6C-1A56FF90C3CBQ28207566-66378A0E-C522-4DF6-9BEE-2B0DED1B5B9BQ28216189-3B579135-7CEB-4FBE-9AEB-88984D99FD52Q28218768-D0374837-BEAA-4DCB-AB52-572D3A0AF253Q28244215-7DFAE507-A7ED-4C80-84D9-195F5306B231Q28269838-2B5F1756-1C52-41D6-ABCA-92F29722D998Q28281217-4A0D8671-9C5E-4CAA-9F34-A56AC3BB848EQ28290241-9D2385C2-8AAC-456A-A0EB-FDBF3408BF0CQ28295050-722ED211-2EB3-4600-96EC-E7A20B020351Q28821191-92D0F33D-3A0D-4DB2-BC00-3709BB540C92Q28821193-5E29AE39-F544-4A98-BAF8-838B9BDE8646Q29540690-8033D6AA-3022-428F-8323-47DDD8F22525Q29999437-E5813352-6CDD-4386-8F73-B45D8BA2C33AQ30151736-D9B0AF5D-81CD-461F-893A-47A44A6D166CQ30238917-3ABED677-35EB-47E8-B213-3630A0B94214Q30326042-02264A88-A0B9-4406-A701-E5870AAD35A3Q30416519-6734DF89-E269-488D-B989-8F2DB247B629Q30561799-8C9B2884-4F37-4133-AD5D-3B860FFE76A8Q30609126-355120A2-A186-4BBF-AD13-C8DBEE822873Q30710766-6F39C3E9-AD3B-4290-BC28-B2D0E59DA08FQ30787553-9F2BF301-7855-4DFC-AF75-51DE69D437A7Q30847410-F3287C82-F8E3-4263-9355-754A3CEF119FQ30871457-A4D3662A-13A6-4AFD-B57B-E0B2A3A517B2Q31060909-CF64C182-5806-4360-AAD4-5AC3E228D70BQ31071930-A3D1E6ED-DE4A-4086-9A42-84E8612094FAQ31153431-835EB616-E498-4571-95D1-688CF8C5575A
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Adis, Springer Healthcare
@nl
wissenschaftliche Fachzeitschrift
@de
name
Drugs in R & D
@ast
Drugs in R & D
@en
Drugs in R & D
@es
Drugs in R & D
@it
Drugs in R & D
@nl
type
label
Drugs in R & D
@ast
Drugs in R & D
@en
Drugs in R & D
@es
Drugs in R & D
@it
Drugs in R & D
@nl
altLabel
Drugs in R&D
@en
Drugs in Research & Development
@en
prefLabel
Drugs in R & D
@ast
Drugs in R & D
@en
Drugs in R & D
@es
Drugs in R & D
@it
Drugs in R & D
@nl
P31
P3181
P1055
P1156
P1277
P1476
Drugs in R & D
@en